Dr. Reddy's to Release Q4 and Full Year FY13 Results on May 14, 2013
Dr. Reddy's to Release Q4 and Full Year FY13 Results on May 14, 2013
Earnings call slated for May 14, 6.30 PM IST / 9.00 AM EDT*
HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy's Laboratories (NYS: RDY) will announce results for the Fourth Quarter and Full year ended March 31, 2013 on Tuesday, May 14, 2013 after the Board Meeting. The results will be available on the Company's website www.drreddys.com
Summary of Events
Event | Date and Time (IST) | Medium | ||||||
Release of financial results | May 14th, after the Board Meeting | Email, Media, Company website, Business Wire | ||||||
Earnings Call | May 14th, 6.30 PM IST / 9:00 AM EDT | Hosted by the Company (Details below) | ||||||
Webcast of Earnings Call | May 14th, 6.30 PM IST / 9.00 AM EDT through May 19th, 2013 | URL available on Company's website, | ||||||
Transcripts of the Earnings call | Will be available on the Company's website | URL available on Company's website, www.drreddys.com | ||||||
Earnings Call
Following the release, the management of the Company will host an earnings call to discuss the Company's financial performance.
Conference Dial-In Numbers | |||
Primary Number: | +91 22 6629 0356 | ||
Secondary Number: | +91 22 3065 0136 | ||
The numbers listed above are universally accessible from all networks and all countries. | |||
Local Access Number: | 6000 1221 Accessible from all major carriers except BSNL/MTNL. 3940 3977 Available in Ahmedabad, Bangalore, Chandigarh, Chennai, Kochi/Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Lucknow, Pune Accessible from all carriers. | ||
International Toll Free Number: | USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 | ||
No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.
Audio Webcast
The audio webcast of the earnings call will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through May 19th, 2013. For play back dial in phone No: 022 3065 1212 and ID: 375#.
Transcript
The transcript of the earnings call will also be available on the Company's website.
About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYS: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets.
For more information, log on to: www.drreddys.com
*EDT- Eastern Daylight Saving Time
Dr. Reddy's Laboratories Ltd.
Investor Relations:
Kedar Upadhye, +91 40 66834297
kedaru@drreddys.com
or
Saunak Savla, +91 40 49002135
saunaks@drreddys.com
or
Milan Kalawadia (USA), +1 908-203-4931
mkalawadia@drreddys.com
KEYWORDS: Asia Pacific India
INDUSTRY KEYWORDS:
The article Dr. Reddy's to Release Q4 and Full Year FY13 Results on May 14, 2013 originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
